AbstractIn search of non‐platinum based anticancer drugs, we have synthesized and characterized a new class of three gadolinium(III)‐oligopeptides [Gd(L1)2(NO3)2][NO3] (1, L1=l‐aspartyl(OMe)‐N‐boc‐l‐aspartyl‐l‐aspartyl (OMe)), [Gd(L2)2(NO3)2][NO3] (2, L2=N‐fmoc‐l‐arginyl‐(Pbf)‐glycyl‐l‐aspartyl(OMe)), [Gd(L3)(NO3)3] (3, L3=N‐fmoc‐l‐arginyl‐(Pbf)‐l‐arginyl(OMe) and a carbon nanotube composite, 1@CNT 4. The three oligopeptides, L1 – L3 were prepared in a novel synthetic route using tetramethyl benzotriazolyl uronium hexaflurophosphate (HBTU) as a peptide coupling reagent. Confocal microscopic analysis of the gadolinium(III)‐oligopeptides, 1, 2 and CNT composite, 1@CNT 4 indicate that they display white and green light emissions upon excitations at λ, 405 and 488 nm with characteristic patterns. The oligopeptides, L1 & L3 display in vitro anticancer activity on HeLa cells with IC50 values in one mM concentration whereas the IC50 of RGD‐based oligopeptide was found to be 1 μM. The IC50 of gadolinium(III)‐oligopeptide, 1 and the CNT composite, 4 were found to be 1 μM and 10 nM. The transmission electron microscopic investigation of the HeLa cells treated with the composite 4 confirm the cellular uptake and indicate the presence of CNTs in the cytoplasm and that CNTs appear like bullets carrying the gadolinium(III)‐triaspartate, 1.
Read full abstract